> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Safety Concerns Stop Eiger Phase 3 Hepatitis Trial
- URL: https://www.fdaweb.com/safety-concerns-stop-eiger-phase-3-hepatitis-trial/
- Published: 2023-09-13T12:00:00.000Z
- Updated: 2026-09-14T18:56:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155315

Eiger Pharmaceuticals says it is discontinuing the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta based on a recommendation from the trial data safety monitoring board. The board recommended on 9/7 that the trial be discontinued due to observations of four patients with hepatobiliary events that resulted in liver decompensation, a company [statement](https://ir.eigerbio.com/news-releases/news-release-details/eiger-discontinue-phase-3-limt-2-trial-peginterferon-lambda?ref=fdaweb.com) says. Company officials said they would work closely with FDA and the trial investigators toward an orderly termination of the study in the interest of patient safety.